Impact of sex on the heart's metabolic and functional responses to diabetic therapies

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 11, 2013, Pages

  Lyons, Matthew R ^a   Peterson, Linda R ^a   McGill, Janet B ^a   Herrero, Pilar ^b   Coggan, Andrew R ^b   Saeed, Ibrahim M ^a   Recklein, Carol ^a   Schechtman, Kenneth B ^a   Gropler, Robert J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Lovaza; Metformin; Myocardial metabolism; Rosiglitazone; Sex; Type

Indexed keywords

FATTY ACID; METFORMIN; METFORMIN PLUS LOVAZA; METFORMIN PLUS ROSIGLITAZONE; OMEGA 3 ACID ETHYL ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FAT FREE MASS; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE METABOLISM; HUMAN; LIPID METABOLISM; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

LOVAZA; METFORMIN; MYOCARDIAL METABOLISM; ROSIGLITAZONE; SEX; TYPE 2 DIABETES;

ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIASTOLE; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ECHOCARDIOGRAPHY, DOPPLER; EICOSAPENTAENOIC ACID; ENERGY METABOLISM; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MISSOURI; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RECOVERY OF FUNCTION; SEX FACTORS; STROKE VOLUME; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84888867456     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00420.2013     Document Type: Article

References (25)

1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 115: 3213-3223, 2007.
2. Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, Sibilio G. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22: 1720-1725, 2005.
3. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, Torp-Pedersen C. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43: 771-777, 2004.
4. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 102: 1083-1091, 1998.
5. Hallsten K, Virtanen KA, Lonnqvist F, Janatuinen T, Turiceanu M, Ronnemaa T, Viikari J, Lehtimaki T, Knuuti J, Nuutila P. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 21: 1280-1287, 2004.
6. Hernandez I, Delgado JL, Diaz J, Quesada T, Teruel MJ, Llanos MC, Carbonell LF. 17β-Estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 279: R1599-R1605, 2000.
7. Herrero P, Soto PF, Dence CS, Kisrieva-Ware Z, Delano DA, Peterson LR, Gropler RJ. Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. J Nucl Cardiol 12: 574-581, 2005.
8. 18F-FDG for quantifying myocardial glucose use with PET. J Nucl Med 43: 1530-1541, 2007.
9. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038, 1979.
10. Kendrick ZV, Ellis GS. Effect of estradiol on tissue glycogen metabolism and lipid availability in exercised male rats. J Appl Physiol 71: 1694-1699, 1991.
11. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 36: 878-884, 2000.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005.
13. Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Luotolahti M, Ball E, Borra R, Harkonen R, Iozzo P, Stewart M, Knuuti J, Nuutila P. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, doubleblind, placebo-controlled study. Diabetes 54: 2787-2794, 2005.
14. Lund LH, Mancini D. Heart failure in women. Med Clin North Am 88: 1321-1345, 2004.
15. Matute ML, Kalkhoff RK. Sex steroid influence on hepatic gluconeogenesis and glucogen formation. Endocrinology 92: 762-768, 1973.
16. Mittendorfer B, Magkos F, Fabbrini E, Mohammed BS, Klein S. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) 17: 1872-1877, 2009.
17. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948, 2003.
18. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109: 2191-2196, 2004.
19. Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, Dence C, Gropler RJ. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 1: 424-433, 2008.
20. Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol 14: 573-581, 2007.
21. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
22. Tuncay E, Seymen AA, Tanriverdi E, Yaras N, Tandogan B, Ulusu NN, Turan B. Gender related differential effects of omega-3E treatment on diabetes-induced left ventricular dysfunction. Mol Cell Biochem 304: 255-263, 2007.
23. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119: 2069-2077, 2009.
24. Zhao X, Eghbali-Webb M. Gender-related differences in basal and hypoxia-induced activation of signal transduction pathways controlling cell cycle progression and apoptosis, in cardiac fibroblasts. Endocrine 18: 137-145, 2002.
25. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784-1789, 2000.